SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply following reports of an upcoming partnership with Novo Nordisk to sell obesity drugs, signaling an end to their prior legal dispute. The unexpected collaboration has the community actively discussing the potential for a significant short squeeze, given the stock's high short interest, and anticipating substantial upside.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership announcement with Hims & Hers to distribute its obesity drugs, ending a prior feud. The community is actively discussing the substantial surge in Hims' stock compared to Novo Nordisk's more modest reaction, raising questions about the deal's implications for the GLP-1 market and competitive landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is gaining significant attention and volume following new listings on major exchanges, positioning it as the utility token for the Solana Mobile "Seeker" smartphone ecosystem. The community is actively discussing breaking key resistance levels with strong bullish conviction, though some caution about potential selling pressure from recent airdrops and staking unlocks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending as community discussion rages over President Trump's "Iran War" and new "Epstein files" allegations, fueling debate about rising gas prices and economic instability, with investors sharply divided on the company's outlook amidst global tensions.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending as community speculation mounts that the departure of a key FDA official may pave an easier regulatory path for its Huntington's disease gene therapy, fueling a significant rally and short squeeze chatter after prior data concerns.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is drawing significant attention as traders position for a decline in crude prices, anticipating that current Middle East geopolitical tensions and the Strait of Hormuz situation will eventually de-escalate, unwinding oil's recent fear premium.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Rithm Capital is actively discussed for its impending S&P SmallCap 600 index inclusion, which analysts anticipate will trigger substantial institutional buying, alongside its consistent earnings beats and strategic evolution into a diversified asset manager. The community is vigorously debating the stock's significant undervaluation and the potential for a future C-Corp conversion or spin-off to unlock considerable shareholder value.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is experiencing a rapid price run-up, leading to polarized community discussions between those anticipating a major AI-driven breakout with connections to the Base network, and others cautioning about potential pump-and-dump dynamics given its past performance and reported red flags.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to significant community optimism following reports of Dr. Vinay Prasad's departure from the FDA, which many believe will foster a more permissive regulatory environment for gene therapies. This development, coupled with CEO Doug Ingram's announced retirement, is fueling M&A speculation and anticipation for upcoming DM1 and FSHD data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iRhythm Technologies (NASDAQ:IRTC) Short Interest Up 20.1% in February

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) saw a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 3,401,218 shares...

iRhythm Technologies (NASDAQ:IRTC) Insider Sells $559,613.08 in Stock

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) insider Patrick Michael Murphy sold 4,357 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average...

Mervin Smith Sells 1,352 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) EVP Mervin Smith sold 1,352 shares of iRhythm Technologies stock in a transaction on Monday, March 2nd. The stock was sold at an average price of...

Insider Selling: iRhythm Technologies (NASDAQ:IRTC) CAO Sells 816 Shares of Stock

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) CAO Marc Wade Rosenbaum sold 816 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of...

iRhythm Technologies (NASDAQ:IRTC) EVP Minang Turakhia Sells 4,027 Shares

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) EVP Minang Turakhia sold 4,027 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average...

Insider Selling: iRhythm Technologies (NASDAQ:IRTC) Insider Sells 4,357 Shares of Stock

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) insider Patrick Michael Murphy sold 4,357 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average...

Chad Patterson Sells 4,444 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) insider Chad Patterson sold 4,444 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of...

iRhythm Technologies $IRTC Shares Sold by Champlain Investment Partners LLC

Champlain Investment Partners LLC trimmed its holdings in iRhythm Technologies (NASDAQ:IRTC - Free Report) by 44.7% during the 3rd quarter, according to the company in its most recent Form 13F filing...

Owlet Stock Before Q4 Earnings: Buy Now or Wait for Results?

OWLT's fourth-quarter results are likely to reflect subscription growth, FDA-backed differentiation and revenue gains, even as tariff pressures weigh on margins.

Mervin Smith Sells 4,041 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) EVP Mervin Smith sold 4,041 shares of iRhythm Technologies stock in a transaction dated Wednesday, February 25th. The stock was sold at an average...

iRhythm Holdings, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.67	--	--	N/A
Q4 '25	$0.01	$0.17	1433.33%	BEAT
Q3 '25	-$0.32	-$0.16	50.64%	BEAT
Q2 '25	-$0.49	-$0.44	10.51%	BEAT
Q1 '25	-$0.96	-$0.97	-0.91%	MISSED

IRTC
iRhythm Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest IRTC News

IRTCiRhythm Technologies Inc